Sangamo Therapeutics, Inc.
SGMO
$0.4831
-$0.0169-3.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 239.92% | -67.20% | -74.04% | -94.38% | -92.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 239.92% | -67.20% | -74.04% | -94.38% | -92.22% |
| Cost of Revenue | -49.67% | -51.35% | -43.29% | -33.52% | -20.19% |
| Gross Profit | 79.13% | -0.18% | -96.48% | -343.46% | -1,265.24% |
| SG&A Expenses | -19.51% | -25.21% | -23.62% | -18.29% | -18.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.37% | -45.94% | -39.26% | -30.39% | -19.85% |
| Operating Income | 65.68% | 13.16% | -25.83% | -108.17% | -199.78% |
| Income Before Tax | 76.11% | 62.68% | 46.92% | -21.65% | -163.20% |
| Income Tax Expenses | 97.17% | 96.71% | 99.74% | 120.24% | -1,014.69% |
| Earnings from Continuing Operations | 75.78% | 62.01% | 45.96% | -25.78% | -157.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 75.78% | 62.01% | 45.96% | -25.78% | -157.97% |
| EBIT | 65.68% | 13.16% | -25.83% | -108.17% | -199.78% |
| EBITDA | 65.80% | 5.13% | -42.50% | -130.60% | -237.72% |
| EPS Basic | 79.75% | 65.09% | 48.60% | -15.81% | -127.01% |
| Normalized Basic EPS | 70.60% | 13.67% | -32.61% | -102.26% | -175.43% |
| EPS Diluted | 79.25% | 64.61% | 48.67% | -14.71% | -123.66% |
| Normalized Diluted EPS | 70.46% | 13.62% | -32.50% | -101.61% | -174.39% |
| Average Basic Shares Outstanding | 18.79% | 15.07% | 12.49% | 11.04% | 10.95% |
| Average Diluted Shares Outstanding | 19.63% | 15.82% | 13.25% | 10.93% | 10.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |